78 results about "Myelin sheath structure" patented technology

The invention provides in vitro cell culture compositions consisting of neurospheres and culture medium, wherein the neurospheres consist of undifferentiated cells that are nestin⁺, glial fibrillary acid protein (GFAP)⁻, neurofilament (NF)⁻, and myelin basic protein (MBP)⁻ and are not nestin⁻.

There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein (MBP) peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.

This invention is directed toward a serum/plasma assay for the diagnosis and subsequent monitoring of patients with multiple sclerosis (MS). Assay performance characteristics indicate that the assay is accurate and repeatable. Using blood from patients with clinically definite multiple sclerosis, a clinical sensitivity of 77% and a specificity of 95% has been achieved through the measurement of circulating myelin basic protein autoantibodies. The assay provides a simple, rapid, and minimally invasive tool for the diagnosis and monitoring of progression of MS.

The present invention relates to agents capable of binding to myelin basic protein in a subject. Also provided are methods for the detection of myelin-associated neuropathy comprising identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, administering to a subject an agent that binds specifically to myelin basic protein, and determining myelination in the subject by detecting the agent present in the subject. A kit containing the agent or its derivatives for use in detecting myelin basic protein is also provided.

Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between amino acid 86 and amino acid 95.

Disclosed are systems for intraoperative nerve imaging using compact high collection power imaging devices for fluorescence and white light imaging of myelin basic protein (MBP) nerve imaging agents during open and minimally invasive surgery.

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

The present invention provides pharmaceutical compositions comprising, as an active ingredient, a substance capable of activating the γ chain of Fc receptors (FcRγ) (provided that the substance is not an immunoglobulin for intravenous injection), and agents for stimulating myelinogenesis. The invention also provides agents for stimulating the differentiation of oligodendroglial precursor cells, agents for activating Fyn tyrosine kinase, and agents for stimulating the expression of myelin basic protein, all comprising a substance capable of activating FcRγ as an active ingredient. Further, the invention provides a method of detecting myelinogenetic oligodenroglias or precursor cells thereof which comprises using the expression of FcRγ in oligodendroglias or precursor cells thereof as an indicator.

The present invention provides compositions and methods for the treatment of multiple sclerosis. Among others, the invention provides compositions of immunodominant peptides of myelin basic protein encapsulated in mannosylated liposomes. In a specific embodiment, the compositions comprise mylein basic protein (MBP) peptides MBP(46-62), MBP(124-139), and MBP(147-170).

The invention relates a separation and detection method of an irradiation product DBP (Double-Base Propellant) and/or MBP (Myelin Basic Protein) in a TBP (Tri-Butyl Phosphate)-kerosene-HNO3 system, which is characterized by comprising the following steps of: firstly, extracting the TBP-kerosene-HNO3 system containing the irradiation product DBP and MBP with a Na2CO3 solution and separating to obtain an organic phase containing a TBP-kerosene-HNO3 system and a Na2CO3 aqueous phase containing DBP, MBP and micro TBP; and secondly, extracting the obtained Na2CO3 aqueous phase containing DBP, MBP and micro TBP with CHCl3 and separating to obtain a CHCl3 organic phase containing micro TBP and a Na2CO3 aqueous phase containing DBP and MBP. The separation and detection method is simple and convenient, does not need expensive instruments and has a short analysis period.

The invention provides a method for preparing a pre-staining luminescent protein marker. The method comprises the following steps: acquiring a protein A gene, a protein G gene, an MBP (Myelin Basic Protein) gene and a heavy chain constant region gene (CH gene) of a mouse and rabbit derived antibody, and cutting and combining the genes according to sizes of different proteins in a pre-staining luminescent protein marker; expressing the proteins, purifying, and mixing proteins of different molecule weights according to a certain ratio so as to obtain a luminescent protein marker; mixing the prepared luminescent protein marker with the pre-staining luminescent protein marker according to different ratios. The pre-staining luminescent protein marker prepared by using the method is capable of recognizing primary antibodies or secondary antibodies of different sources, binding sites of proteins are increased, light signals are intensified, not only are general positions of proteins indicated in the electrophoresis process and after membrane transfer, but also precise positions of the proteins can be indicated on X-ray films, no extra pre-staining marker channels are needed, no extra antibodies are needed, and the luminescent proteins can be combined with IgG or anti-rabbit and anti-mouse secondary antibodies derived from species such as human beings, rats, mice and rabbits.

The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein

The present invention relates to methods for myelin basic protein detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the agent, and determining myelination in the subject by detecting binding to myelin basic protein. Methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using an agent with specific binding to myelin basic protein are also provided as is a kit containing the agent or its derivatives for use in detecting myelin basic protein

A Myelin Basic Protein-luciferase bioimaging noninvasive model to visualize and quantify demyelination and remyelination events in the CNS at transcriptional level in vivo is provided. Luciferase-expressing transgenic animals were generated with myelin basic protein (MBP) promoter coupled to firefly luciferase reporter. The MBP-luci bioimaging model provides a means to monitor myelination status and the efficacy of a remyelination modulating test compound. An advantage of bioimaging is that a subject in a longitudinal study can serve as its own control. The same subject can be tracked over a demyelination and remyelination process continuously over a period of at least 10 weeks. This model enables normalization of individual animal imaging response and provides quality data with considerably reduced variance. In addition, because cohorts of animals need not be sacrificed at different time points, reduction in the number necessary for a compound efficacy study is possible.

The invention relates to recombinant human acidic fibroblast growth factor (FGF1), in particular relates to a preparation method of FGF1 full-length protein by utilizing escherichia coli, which comprises the following steps of amplifying by utilizing a PCR (polymerase chain reaction) method to obtain a human FGF1 full-length gene PCR product; and digesting the PCR product by using incision enzyme. According to the preparation method, the full-length gene of the human acidic fibroblast growth factor is cloned to a pMAL-p5X expression carrier; the recombinant plasmid expresses the FGF1 full-length protein containing MBP (myelin basic protein) fusion label at high efficiency in the escherichia coli, wherein the protein in soluble expression; and the protein with MBP infusion label is purified by utilizing an MBP affinity column, and a complete FGF1 protein without the fusion label is prepared by utilizing TEV (tobacco etch virus) enzyme binding site and using TEV digested and purified infusion protein. The FGF1 full-length protein has high solubility and higher purity.

The invention discloses a method for embedded membrane expression and aquaporins (AqpZ) purification in escherichia coli. According to the method, firstly, AqpZ- histidine (HIS) of the escherichia coli is amplified, then, recombination expression vectors and inducible expression engineering bacterial strains are constructed, fusion protein myelin basic protein (MBP)-AqpZ-HIS thalli are obtained through ultrasonic crushing, and finally, the AqpZ is obtained through purification. The method has the advantages that the efficient expression of maltose-binding protein-AqpZ-poly histidine binary tag fusion protein is realized in the escherichia coli, and the problems of insoluble inclusion body forming and host cell toxicity caused by the traditional overexpression AqpZ are solved; and in addition, high-purity AqpZ can be obtained only through two turns of simple affinity chromatography separation on the AqpZ expressed by the method, the operation is simple, and the method can be applied to industrial production.

A method and a kit for detecting myelin basic protein are provided. The method comprises administering an agent, which binds to myelin basic protein (MBP), to a subject at risk of or diagnosed with a myelin-associated neuropathy, and determining myelination by detecting the agent resided in the subject. The amount of the agent present in the subject is indicative of a myelin-associated neuropathy. A method of quantifying an amount of MBP present in a tissue sample is also provided, wherein the method comprises contacting the tissue sample with the same agent, detecting the agent present in the tissue sample; and quantifying an amount of the agent present in the tissue sample.

A method of detecting the presence, or monitoring the severity of a condition characterised by the presence of fragments of a marker protein in the brain of a patient. The method comprises: (i) providing a sample comprising macrophages obtained from the patient; and (ii) detecting the presence of the marker protein or fragments thereof in the macrophages. The presence of abnormal levels of the marker protein and/or fragments thereof in the macrophages is indicative of the presence of the condition in the patient. The condition and the marker proteins can be: Alzheimer's Disease and the Abeta peptide, Parkinson's Disease and ubiquitin, Multiple Sclerosis and myelin basic protein, FrontoTemporal Dementia and tau, Amyotrophic Lateral Sclerosis and tau, Parkinson's disease, Lewy Body dementia or Alzheimer's Disease and alpha-synuclein.